Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-…
Industry Peers
Drug Manufacturers - Specialty & Generic| Headline | Source | Time |
|---|---|---|
Today | ||
 Eton Pharmaceuticals (ETON) Q2 2026 Earnings Call Transcript Revenue surged 99% year-over-year on HEMANGEOL relaunch and rare disease portfolio growth. | ||
Older | ||
 Is Eton Pharmaceuticals (ETON) Fully Priced On Strong Q2 Results And Raised Guidance? Eton Pharmaceuticals (ETON) has become a focus for investors after its second quarter 2026 report, which showed US$37.59 million in revenue, US$11.58 million in net income, and a shift from loss to earnings per share. See our latest analysis for Eton Pharmaceuticals. The strong Q2 results and raised 2026 guidance have coincided with a sharp re-rating in Eton Pharmaceuticals, with a 1 day share price return of 44.26% helping extend its year to date share price return to 261.99%, while the 3... | ||
Sector Update: Healthcare Stocks Decline Late Afternoon Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index decreasing 0.4% a | MMT Newswires | |
 Why Eton Pharmaceuticals Is Top of the Class Today Eton's cure for an expensive valuation: a 99% sales growth rate. | ||
 This Analyst Believes Eton Pharma’s Raised Guidance Is ‘Conservative’ – ETON Stock Heads For Best Ever Day Eton expects full-year 2026 revenue to exceed $145 million, up from its previous forecast of more than $120 million. | ||
 Why Top 3% Biotech Stock, Eton, Just Catapulted To A Record High Eton stock catapulted to a record high Friday after the biotech company smashed second-quarter sales forecasts and hiked its guidance. | ||
 Eton Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary Moby summary of Eton Pharmaceuticals, Inc.'s Q2 2026 earnings call | ||
Eton Pharmaceuticals Inc (ETON) (Q2 2026) Earnings Call Highlights: Record Revenue and ... Eton Pharmaceuticals Inc (ETON) reports a 99% revenue surge to $37.6 million, raises full-year guidance, and advances key pipeline assets. | ||
 Eton Pharmaceuticals Q2 Earnings Call Highlights Eton Pharmaceuticals (NASDAQ:ETON) reported second-quarter revenue nearly doubled from a year earlier, driven by the relaunch of HEMANGEOL and growth across its pediatric endocrinology and rare-disease portfolio. The company raised its full-year revenue and profitability outlook while outlining plan | ||
 Eton Pharmaceuticals, Inc. (ETON) Q2 Earnings and Revenues Beat Estimates Eton Pharmaceuticals (ETON) delivered earnings and revenue surprises of +218.18% and +38.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates Insmed (INSM) delivered earnings and revenue surprises of +24.64% and +9.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 ETON Stock Jumps 10%: Why Does This Analyst See 47% Upside To Stock? Craig-Hallum on Tuesday lifted its price target on ETON to $62 from $40 and kept a Buy rating. | ||
 Eton Pharmaceuticals (ETON) Moves 13.8% Higher: Will This Strength Last? Eton Pharmaceuticals (ETON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. | ||
 Apple upgraded, Brinker initiated: Wall Street's top analyst calls Apple upgraded, Brinker initiated: Wall Street's top analyst calls | TThe Fly | |
IInsider Monkey | ||